Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

950
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
950
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

854
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
854
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

642
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
642
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

651
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
651
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

997
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
997

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased risk of <i>de novo</i> inflammatory bowel disease following cholecystectomy: a population-based analysis.

Annals of gastroenterology·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.

Gastro hep advances·2026
Same author

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same author

Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study.

Inflammatory bowel diseases·2026
Same author

Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine.

Vaccine·2026
Same author

Guidelines in Practice: Preventive Care in Inflammatory Bowel Disease.

The American journal of gastroenterology·2026

Related Experiment Video

Updated: Apr 3, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.2K

Ulcerative Colitis: Update on Medical Management.

Heba N Iskandar1, Tanvi Dhere2, Francis A Farraye3

  • 1Department of Medicine, Division of Digestive Diseases, Emory University, 1365 Clifton Rd. NE, Building B, Suite 1200, Atlanta, GA, 30322, USA. heba.iskandar@emoryhealthcare.org.

Current Gastroenterology Reports
|September 21, 2015
PubMed
Summary

Recent advances in ulcerative colitis (UC) management include new therapies and improved diagnostic tools. This review highlights key developments in monitoring disease activity and detecting dysplasia for better patient outcomes.

Keywords:
Health maintenance in ulcerative colitisInflammatory bowel diseaseNew therapies in ulcerative colitisUlcerative colitisUlcerative colitis treatment

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Related Experiment Videos

Last Updated: Apr 3, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.2K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Medicine

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with complex, multifactorial origins involving genetic, environmental, and gut microbiome factors.
  • Managing UC has seen significant improvements due to recent diagnostic and therapeutic advancements.
  • Effective disease monitoring strategies, including therapeutic drug monitoring, stool markers, and mucosal healing assessments, are crucial.

Purpose of the Study:

  • To review recent advancements in the diagnosis and management of ulcerative colitis.
  • To highlight new therapeutic options and diagnostic techniques for UC patients.
  • To discuss the evolving landscape of UC treatment and surveillance.

Main Methods:

  • Review of recent scientific literature and clinical trial data on ulcerative colitis.
  • Analysis of new therapeutic agents and diagnostic modalities.
  • Inclusion of consensus statements and guidelines for UC management.

Main Results:

  • The approval of vedolizumab offers a new biologic treatment for moderate to severe UC.
  • Emerging therapies targeting the Janus tyrosine kinase (JAK) pathway are expanding treatment options.
  • The SCENIC consensus statement recommends chromoendoscopy over random biopsies for dysplasia surveillance in UC.

Conclusions:

  • Recent progress has significantly improved the management of ulcerative colitis.
  • A growing number of therapeutic and diagnostic tools are available for UC patients.
  • Continued research and guideline updates are essential for optimizing UC care.